SEP-4199

Phase 2Small molecule

Sumitomo Pharma America, Inc.

SEP-4199 is one of 12 small molecule programs targeting Major Depressive Episode. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Major Depressive EpisodeActive, not recruiting

Major Depressive EpisodePhase 2

Active, not recruiting

Competition

Competitive Landscape

13 competitors in Major Depressive Episode

#DrugCompanyPhaseTrials

Ketalar

AAultman Health Foundation

Vimpat

1 3

Brintellix

Takeda

Phase 3

1 4

Abilify

Otsuka

Phase 3

2 5

Suboxone

IIndivior Inc.

Phase 3

1 6

FK949E

Astellas

Phase 3

2 7

SAGE-217

Biogen

Phase 2

1 8

Lithobid

SSolvay Pharmaceuticals

Preclinical

1 9

SEP-4199

Sumitomo Pharma America, Inc.

Phase 2

3 10

MAP4343

TThe Scripps Research Institute

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Major Depressive Episode3 trials

A Clinical Study to Test the Effectiveness of an Investigational Drug to Treat People That Have Major Depressive Episodes When They Have Bipolar 1 Depression

Completed· Sumitomo Pharma America, Inc. logo

Sumitomo Pharma America, Inc.·Phase 2·NCT03543410·344 enrolled

A Clinical Trial to Determine the Long-term Safety and Tolerability of an Investigational Drug in People With Major Depressive Episode Associated With Bipolar I Disorder (Bipolar I Depression).

Terminated· Sumitomo Pharma America, Inc. logo

Sumitomo Pharma America, Inc.·Phase 3·NCT05227209·64 enrolled

A Clinical Study of an Investigational Drug for the Treatment of Major Depressive Episode Associated With Bipolar I Disorder.

Terminated· Sumitomo Pharma America, Inc. logo

Sumitomo Pharma America, Inc.·Phase 3·NCT05169710·83 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for SEP-4199. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SEP-4199 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SEP-4199. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sumitomo Pharma America, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Sumitomo Pharma America, Inc.

SEP-4199

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Major Depressive Episode3 trials

References

Drug Info

Quick Facts

Related News